Inhibition of IL-6, a key mediator of the inflammatory process in CS and a prognostic marker in COVID-19, with IL-6 receptor inhibitors including tocilizumab and sarilumab has shown its efficacy in the severe COVID-19 stages [1,48]. This evidence concerns the gene IL6 and COVID-19.